The winning enterprises in safety risk prevention and control are rewarded, and the company makes requirements for safety risk assessment and prevention and control.
Release time:
2023-05-04
After two rounds of employee safety risk knowledge assessment and inspection assessment, Daye Peak, Cable Company and Pharmaceutical Manufacturing Department won the top three in the 2022 safety risk prevention and control evaluation. Jiang Xiaomeng, chairman of the group company, and Yu Jianhong, general manager of the group company, respectively awarded awards to the winning enterprises. The
meeting commented on the safety risk assessment and prevention and control work of various enterprises, shared and introduced the outstanding highlights, and asked all enterprises to learn from it. From four aspects: the implementation of risk classification control and the existing problems, the distinction between risk sources and potential safety hazards, the current operation of the dual prevention mechanism, and how to carry out risk analysis of unconventional operations, to further deepen the implementation of safety risk prevention and control work to do a detailed explanation. Yu Jianhong, general manager of
Group Company, stressed at the meeting that managers at all levels should attach importance to safety management from the perspective of enterprise development, enterprise competitiveness and personal career. Safety management must move forward, and safety risk assessment must be strictly carried out. He said that the company inspection is a test of the safety management of the company. The purpose is to urge all production companies to adopt a scientific and reasonable method to accurately assess the safety risks of each position. The implementation of the system in daily management, risk investigation and rectification must rely on the company itself. Complete, all companies must further clarify the purpose of the company's safety inspection, get rid of dependence, and do the risk assessment work in a down-to-earth manner, the operation procedures and prevention work should be put in place, and the daily inspection and rectification should be put in place, so as to truly achieve the purpose of promoting the progress of management and technology and improving the safety and security of enterprises. Jiang Xiaomeng, chairman of
Group Company, requested at the meeting that all companies should carefully analyze the recent major accident cases in Beijing, Wuyi and other places, learn lessons, and strengthen the investigation and rectification of potential safety hazards; strengthen various forms of education and training, Enhance employee safety awareness, improve employee safety quality, and match employee safety skills with the development and application of new products and technologies; strengthen the publicity and implementation of the system, increase the frequency of inspections, increase the intensity of assessments, and let every employee feel the pressure and responsibility; we must further improve safety management with a "heart" attitude, strive to prevent safety accidents from happening, and ensure the smooth operation of the company.
21
, the company's safety Committee also organized some safety production leaders and safety officers of subordinate enterprises to visit and study in Hangzhou shanya south cement company. (Ni Zhenyu)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page